Our leadership team, including recognized physician experts and researchers, is at the forefront of shaping new standards of cancer care based upon the latest research. Patients are at the heart of everything we do. Sarah Cannon offers integrated cancer services, providing patients with cutting-edge treatments and upholding the highest quality care for patients from diagnosis through survivorship.
Ian W. Flinn, MD, PhD
Director, Lymphoma Research; Principal Investigator
Dr. Flinn joined Sarah Cannon in 2006 and serves as the director of lymphoma research. In his role, he oversees blood cancer research throughout Sarah Cannon and its affiliates. Flinn also serves as the director for the Sarah Cannon Center for Blood Cancer at Tennessee Oncology and TriStar Centennial Medical Center.
Flinn received his bachelor's degree in economics from Georgetown University in Washington, D.C. in 1984 and graduated from Johns Hopkins University School of Medicine in Baltimore in 1990. He then completed his internship and residency at the University of Michigan Medical Center in Ann Arbor. He earned a fellowship in oncology and hematology and a PhD in clinical investigations from Johns Hopkins University School of Medicine. He is board certified in hematology and medical oncology. Additionally, Flinn is an associate with Tennessee Oncology, PLLC.